Oxford Biomedica's next CEO to start in March; Kåre Schultz ready to wrap up Teva tenure early

Oxford Biomedica's next CEO to start in March; Kåre Schultz ready to wrap up Teva tenure early

Submitted by admin on November 23, 2022 - 7:36am
Source: 
Endpoints
News Tags: 
Pharma CEOs
Frank Mathias
Oxford BioMedica
Kåre Schultz
Teva Pharmaceutical
Richard Francis
Headline: 
Oxford Biomedica's next CEO to start in March; Kåre Schultz ready to wrap up Teva tenure early
snippet: 

 Frank Mathias is calling it quits as CEO of German CDMO Rentschler Biopharma, moving instead to UK gene and cell therapy player Oxford Biomedica in March 2023. 

Do Not Allow Advertisers to Use My Personal information